VR Logo

Soleno Therapeutics Inc. (SLNO) download report


Healthcare | Biotechnology & Pharma Research

Soleno Therapeutics Inc. (SLNO) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

IPO Date: 13-Nov-2014

Pres, CEO, COO & Director: Dr. Anish Bhatnagar M.D.

Chief Financial Officer: Mr. James H. MacKaness

Listing: NASDAQ: SLNO

Country: United States

Headquarters: Redwood City, CA

Website: https://soleno.life

Key Facts

Market cap: $20.40 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-27.68 Mln

Cash: $28.97 Mln

Total Debt: $0.42 Mln

Insider's Holding: 15.27%

Liquidity: Low

52 Week range: $0.13 - 1.23

Shares outstanding: 120,089,000

10 Years Aggregate:

  • CFO: $-124.67 Mln
  • EBITDA: $-102.58 Mln
  • Net Profit: $-167.36 Mln

Stock Performance

Time Period Soleno Therapeutics (SLNO) S&P BSE Sensex S&P Small-Cap 600
YTD-60.44-9.49-17.79
1 month-18.82-2.87-2.72
3 months-45.93-8.59-12.17
1 Year-85.250.81-15.82
3 Years-61.1210.397.14
5 Years-43.0611.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Soleno Therapeutics (SLNO) S&P Small-Cap 600 S&P BSE Sensex
2021-78.7625.2721.99
2020-34.359.5715.75
201971.9320.8614.38
2018-4.97-9.705.87
2017-55.5611.7327.91
2016-56.2224.741.95
201524.03-3.36-5.03